COP1 and GSK3β Cooperate to Promote c-Jun Degradation and Inhibit Breast Cancer Cell Tumorigenesis  by Shao, Jing et al.
COP1 and GSK3β Cooperate
to Promote c-Jun Degradation
and Inhibit Breast Cancer
Cell Tumorigenesis1,2
Jing Shao*,†, Yong Teng‡, Ravi Padia†,
Sungguan Hong†, Hyangsoon Noh†, Xiayang Xie§,
Jeff S. Mumm§, Zheng Dong§, Han-Fei Ding‡,
John Cowell‡, Jaejik Kim‡,¶, Jiahuai Han*
and Shuang Huang†,#
*State Key Laboratory of Cellular Stress Biology, School
of Life Sciences, Xiamen University, Xiamen, Fujian,
China; †Department of Biochemistry and Molecular Biology,
Medical College of Georgia, Georgia Regents University,
Augusta, GA; ‡Cancer Center, Georgia Regents University,
Augusta, GA; §Department of Cellular Biology and Anatomy,
Medical College of Georgia, Georgia Regents University,
Augusta, GA; ¶Department of Biostatistics, Georgia
Regents University, Augusta, GA; #E-Institute of Shanghai
Municipal Education Committee, Shanghai University
of Traditional Chinese Medicine, Shanghai, China
Abstract
High abundance of c-Jun is detected in invasive breast cancer cells and aggressive breast tumor malignancies. Here,
we demonstrate that a major cause of high c-Jun abundance in invasive breast cancer cells is prolonged c-Jun
protein stability owing to poor poly-ubiquitination of c-Jun. Among the known c-Jun–targeting E3 ligases, we iden-
tified constitutive photomorphogenesis protein 1 (COP1) as an E3 ligase responsible for c-Jun degradation in less
invasive breast cancer cells because depletion of COP1 reduced c-Jun poly-ubiquitination leading to the stabilization
of c-Jun protein. In a panel of breast cancer cell lines, we observed an inverse association between the levels of COP1
and c-Jun. However, overexpressing COP1 alone was unable to decrease c-Jun level in invasive breast cancer cells,
indicating that efficient c-Jun protein degradation necessitates an additional event. Indeed, we found that glycogen
synthase kinase 3 (GSK3) inhibitors elevated c-Jun abundance in less invasive breast cancer cells and that GSK3β
nonphosphorylable c-Jun–T239A mutant displayed greater protein stability and poorer poly-ubiquitination compared
to the wild-type c-Jun. The ability of simultaneously enforced expression of COP1 and constitutively active GSK3β to
decrease c-Jun abundance in invasive breast cancer cells allowed us to conclude that c-Jun is negatively regulated
through the coordinated action of COP1 and GSK3β. Importantly, co-expressing COP1 and active GSK3β blocked
in vitro cell growth/migration and in vivometastasis of invasive breast cancer cells. Gene expression profiling of breast
tumor specimens further revealed that higher COP1 expression correlated with better recurrence-free survival. Our
study supports the notion that COP1 is a suppressor of breast cancer progression.
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Introduction
c-Jun is a member of the activating protein 1 family of transcription
factors [1]. By forming heterodimers with other members of activat-
ing protein 1 family, c-Jun regulates the expression of a variety of
genes important for diverse cellular functions including cell growth,
cell migration, and invasion [2]. As one of the first identified proto-
oncogenes, extensive studies have been exerted to characterize the
role of c-Jun in cancer development including breast cancer. An early
study showed that forced c-Jun expression was able to convert non-
invasive/hormone-dependent breast cancer MCF7 line to an inva-
sive and hormone-resistant line [3]. A later study using clinical breast
tumor specimens revealed that c-Jun was detected in the invasive front
of breast tumors and its level correlated with increased angiogenesis
[4]. The role of c-Jun to promote breast tumor progression and metas-
tasis is supported by two recent in vivo studies: 1) depletion of c-Jun
reduced cell migration and invasion of ErbB2-induced mammary
tumors in ErbB2 mammary tumor transgenic mouse model [5] and
2) overexpression of c-Jun was sufficient to confer nonmetastatic
breast cancer cells with the capability to metastasize [6]. An active
role of c-Jun in breast tumorigenesis may lie in its ability to promote
cell proliferation [7] and migration/invasion [8].
High abundance of c-Jun is detected in various aggressive tumor
types [9,10]. Immunohistochemistry revealed that c-Jun level was
often low and present in only few cells of normal and benign breast
tissues; in contrast, immunoreactivity of c-Jun was detected at high
intensity and usually detected in a significant percentage of cells in breast
carcinoma specimens [11]. With the limited number of human breast
cancer cell lines, we previously showed that the amount of c-Jun is much
higher in invasive lines than less invasive ones [8]. Although the abun-
dance of c-Jun may be governed at transcriptional, posttranscriptional,
translational, and posttranslational levels [2], the mechanism behind
elevated c-Jun level in invasive breast cancer cells is not well understood.
Under the normal circumstances, c-Jun protein is known to
be highly unstable [12] and its level can be regulated through a
ubiquitination/proteasome-dependent mechanism [13]. Ubiquitin E3 li-
gases that can add poly-ubiquitin chain on c-Jun include constitutive
photomorphogenesis protein 1 (COP1) [14], cullin 4 (CUL4) [15],
F-box and WD repeat domain containing 7 E3 ubiquitin protein ligase
(FBW7) [16], Itchy E3 ubiquitin protein ligase (ITCH) [17], mitogen-
activated protein kinase kinase kinase 1 (MEKK1) [18], and sensitive to
apoptosis, zinc ring finger protein (SAG) [19]. COP1 is unique from
others because of its dual ability to act as an E3 ligase as well as an adaptor
to recruit substrate to de-etiolated homolog 1/damage-specific DNA
binding protein 1/cullin 4/ring-box 1, E3 ubiquitin protein ligase
(DET1/DDB1/CUL4/RBX1) ubiquitin ligase complex [15]. The ex-
pression of E3 ligases often displays tissue specificity and varies in various
types and stages of cancers; therefore, it is of great interest to investigate
whether one or more of these c-Jun–targeting E3 ligases are involved
in the regulation of c-Jun protein abundance in breast cancer cells.
Function of c-Jun has been shown to be regulated by phosphoryla-
tion. Casein kinase II phosphorylates c-Jun, leading to the suppres-
sion of c-Jun activity [20]. In contrast, c-Jun N-terminal kinases
(JNKs) activate c-Jun by directly phosphorylating c-Jun [21]. Interest-
ingly, JNKs also activate c-Jun–targeting E3 ligase ITCH, thereby estab-
lishing a negative feedback loop [17]. Recognition of c-Jun by E3 ligase
FBW7 and subsequent degradation necessitate c-Jun first being phos-
phorylated by glycogen synthase kinase 3 beta (GSK3β) [22]. However,
it is unknownwhether c-Jun phosphorylation is a prerequisite for its deg-
radation by COP1 and others.
The objective of this study was to answer how the protein level of
c-Jun is regulated in breast cancer cells. By performing cycloheximide-
chasing experiment, we found that c-Jun protein was much more
stable in invasive breast cancer cells than in less invasive ones. Pro-
longed c-Jun protein stability was due to much less c-Jun being
poly-ubiquitinated in invasive breast cancer cells. To characterize the
mechanism mediating c-Jun protein degradation, we showed that
either depleting COP1 or inhibiting GSK3 activity prevented poly-
ubiquitination of c-Jun and increased c-Jun abundance in less invasive
breast cancer cells. Moreover, only simultaneous enforcement of
COP1 and constitutively active GSK3β (GSK3βS9A) expression was
able to effectively downregulate c-Jun in invasive breast cancer cells.
These results indicate that both high COP1 expression and GSK3β-
mediated phosphorylation were necessary for c-Jun protein turnover.
This notion was supported by the observation that non–GSK3β-
phosphorylable c-Jun was significantly more stable than wild-type
c-Jun. Importantly, we showed that co-expressing COP1 and
GSK3βS9A suppressed both in vitro cell growth/migration and in vivo
metastasis of invasive breast cancer cells. Gene expression analysis of
breast tumor specimens further revealed that COP1 mRNA expres-
sion is an independent positive prognostic factor of recurrence-free
survival of patients with breast cancer.
Materials and Methods
Cell Culture, Inhibitors, and siRNAs
All cell lines used in the study were purchased from American Tissue
Culture Collection (ATCC,Manassas, VA) and cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS in a humidi-
fied atmosphere containing 5% CO2 at 37°C. Inhibitors used in the
study were PYR-41 from Calbiochem (San Diego, CA); MG132 and
Chloroquine from Tocris (Bristol, United Kingdom); SP600125,
SB216763, and 4,5,6,7-tetrabromobenzotriazole (TBB) from Sigma
(St Louis, MO). All E3 ligase–targeting siRNAs and control siRNA
were purchased from Thermo Scientific (West Palm Beach, FL).
Determination of c-Jun Protein Stability
Overnight cultured MCF7, MDA-MB-231, MDA-MB-436,
and T47D cells were co-transfected with plasmids encoding human
influenza hemagglutinin (HA)-tagged c-Jun and green fluorescent
protein (GFP) for 1 day. Cells were trypsinized and reseeded for
12 hours followed by addition of 10 μg/ml cycloheximide. At vary-
ing time points, cells were harvested and cell lysates were subjected
to immunoblot analysis to detect HA-tagged c-Jun and GFP using
respective antibodies. The intensities of bands were quantified by
Odyssey Image System (LI-COR Biosciences, Lincoln, NE).
Immunoprecipitation
To determine c-Jun poly-ubiquitination in breast cancer cells,
HA-tagged c-Jun and Flag-tagged ubiquitin were co-transfected into
MDA-MB-231, MDA-MB-436, MCF7, and T47D cells for 1 day
followed by the treatment of MG132 for 8 hours. Cells were lysed in
buffer containing 1% sodium dodecyl sulfate, 150 mM NaCl, and
10 mM Tris-HCl (pH 8.0) followed by 10-minute boiling. Samples
were sheared with a sonication device and diluted in buffer contain-
ing 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, and
1% Triton X-100. After a 30-minute centrifugation at 20,000g, the
resulting supernatants were immunoprecipitated with HA monoclonal
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antibody (mAb) and immunoprecipitates were subjected to immuno-
blot analysis to detect Flag-ubiquitin using Flag mAb.
Cell Fractionation
Cell fractionation was performed as we previously described
[23]. Briefly, cells were lysed in Buffer A [10 mM Hepes (pH 7.9),
1.5 mM MgCl2, 10 mM KCl, 0.5 mM PMSF, and 0.5 mM DTT]
followed by centrifugation at 2000g for 10 minutes to obtain a crude
nuclear pellet and a cytoplasmic supernatant (cytoplasmic fraction).
The crude nuclear pellets were purified further by resuspension in
Buffer B [20 mM Hepes (pH 7.9), 25% (vol/vol) glycerol, 0.45 M
NaCl, 1.5 mM MgCl2, 1 mM EDTA, 0.5 mM PMSF, and
0.5 mM DTT]. The lysates were subjected to high-speed centrifuga-
tion for 1 hour to obtain nuclear fraction.
Lentiviral Constructs and Packaging
Coding sequences of COP1 and GSK3βS9A mutant were sub-
cloned into pCDH Lentivector (System Biosciences, Mountain View,
CA). Lentiviruses were packaged in 293FT cells according to the
manufacturer’s instruction.
Nuclear Proteasome Activity Assay
Nuclear 20S proteasome activities were determined using overnight
cultured cells with the aid of 20S Proteasome Assay Kit (Cayman
Chemical, Ann Arbor, MI) that measures the ability of the fractions
to cleave proteasome-specific substrate SUC-LLVY-AMC. Briefly, cells
were resuspended in Buffer A [10 mM Hepes, 10 mM KCl, 2 mM
MgCl2, 0.1 mM EDTA, and 1 mM PMSF (pH7.9)] and incubated
on ice for 25 minutes followed by adding 10% NP-40 to the final
concentration of 1%. Cells were vortexed for 15 seconds and then
microcentrifuged at 5000g for 5 minutes. The collected pellets (cell
nucleus) were analyzed for 20S proteasome activity.
Immunofluorescence Staining
Cells were culture on collagen-coated glass coverslips overnight,
then fixed with 4% paraformaldehyde and permeabilize with 1%
Triton X-100 for 15 minutes. To visualize c-Jun and proteasome
S5A subunit, coverslips were incubated with c-Jun mAb and S5A
polyclonal antibody followed by incubation with fluorescein isothio-
cyanate or rhodamine-labeled secondary antibodies. The fluorescence
staining was visualized under a fluorescence microscope (Axiovert
200M; Zeiss, Munich, Germany). 4′,6-Diamidino-2-phenylindole
(DAPI) was used to stain nucleus of breast cancer cells.
Cell Proliferation Study
To determine the ability of enforced COP1 and GSK3βS9A
expression to affect cell proliferation, MDA-MB-231 and MDA-
MB-436 cells were transduced with empty lentiviral vector or vector
containing COP1 or GSK3βS9A for 3 days. Transduced cells were
subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay to evaluate cell proliferation as previously
described [23]. Briefly, 5 × 104 cells were seeded into 24-well cul-
ture plates and allowed to grow for 1 to 3 days before the addition
of MTT. Cell proliferation was determined by reading plates at
595 nm after dissolving MTT formazan with DMSO.
Cell Migration Assay
The ability of enforced COP1 and GSK3βS9A expression to affect cell
migration of MDA-MB-231 and MDA-MB-436 cells was determined
using 24-well formatted collagen-coated transwell as we previously
described [8]. Briefly, 1 × 105 cells in 100 μl of serum-free medium
were added into the upper chamber of each transwell and allowed to
migrate for 4 hours. Nonmigrating cells in the upper chambers were
removed by cotton swabs, and migrating cells on the lower surface of
the chamber were stained using crystal violet. Amount of migrating
cells was determined by counting the stained cells under a phase-
contrast microscope.
Zebrafish Metastatic Model
The effect of combined expression of COP1 and GSK3βS9A was
evaluated by a recently developed zebrafish metastatic model [24].
All experimental procedures were approved by the Institutional
Animal Care andUse Committee ofGeorgia Regents University. Briefly,
control or COP1/GSK3βS9A-expressing MDA-MB-231 cells were
first labeled with fluorescent dye CM-Dil (Life Technologies, Carlsbad,
CA), and approximately 200 labeled cells were then microinjected
into the perivitelline space of 48-hour post fertilization (hpf) zebrafish
embryos using a pressure microinjector. The embryos were kept at
34°C and then imaged under anaesthetic by confocal microscopy at
48-hour post injection.
Statistical Analysis
Statistical analyses of laboratory studies were performed by either
Student’s t test or analysis of variance. To determine the potential
correlation between COP1 expression and clinicopathologic param-
eters, we obtained data of COP1 expression in microarray analysis
and clinical features of 126 patients with breast cancer who re-
ceived tamoxifen monotherapy, chemotherapy, and radiation therapy
from the Gene Expression Omnibus database (91 samples from
GSE18229 and 35 samples from GSE40954). The cutoff value of
high and low COP1 expression groups was based on the median
value. Associations between COP1 expression and clinicopathologic
parameters were determined using Pearson χ2 test. In univariate sur-
vival analysis, the Kaplan-Meier method and log-rank test were used
to compare recurrence-free survival curves between high and low
COP1 expression groups. In multivariate survival analysis, the Cox
proportional hazard regression model was used to identify important
factors on disease-free survival. To identify these factors, an initial
model with only COP1 expression was considered and a particular
clinicopathologic parameter was added to the model at a time. By
repeating this procedure, the final regression model with important
factors was identified by likelihood ratio test. P < .05 was considered
statistically significant.
Results
Ubiquitin/Proteasome-Dependent Mechanism Controls
c-Jun Abundance in Breast Cancer Cells
With limited human breast cancer cell lines, we previously showed
that the abundance of c-Jun was much higher in invasive breast can-
cer cells than in less invasive ones [8]. To extend this early finding,
we performed immunoblot analysis to examine c-Jun abundance
in 10 established breast cancer cell lines that included 5 invasive and
5 less invasive lines (Figure 1B). High level of abundance of c-Jun
was seen in all invasive lines, while it was low or barely detectable
in less invasive cell lines (Figure 1, A and B). To determine whether
there was any difference in c-Jun protein stability between invasive
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and less invasive lines, we co-transfected HA-tagged c-Jun and GFP
into two invasive (MDA-MB-231 and MDA-MB-436) and two less
invasive lines (MCF7 and T47D) followed by performing cyclo-
heximide-chasing experiment to measure the stability of HA-tagged
c-Jun protein in these lines. HA-tagged c-Jun was relatively stable
and we detected no more than 40% reduction in the amount of
HA-tagged c-Jun in MDA-MB-231 and MDA-MB-436 cells after
2 hours of cycloheximide addition (Figure 1C ). In contrast, more
than 80% of HA-tagged c-Jun was degraded in the same time
period in T47D and MCF7 cells (Figure 1C). Because GFP exhibited
similar protein stability in both invasive and less invasive lines (Fig-
ure 1C ), these results indicate that greater c-Jun protein stability
is a contributing factor to high c-Jun abundance in invasive breast
cancer cells.
c-Jun protein can be degraded through a ubiquitin/proteasome-
dependent mechanism in various cell types, including melanoma
and lung cancer cells [25,26]. To determine whether ubiquitin/
proteasome system plays a role in regulating c-Jun abundance in breast
cancer cells, we treated MCF7, MDA-MB-231, MDA-MB-436, and
T47D cells with either ubiquitin E1 ligase inhibitor PYR-41 [27]
or proteasome inhibitor MG132 for 8 hours. Immunoblot analysis
showed that treatment of either inhibitor markedly increased the
Figure 1. Abundance of c-Jun in breast cancer cells is determined by its protein stability. (A) Immunoblot analysis of c-Jun in breast cancer
cell lines. (B) In vitro invasion of breast cancer cell lines. Data are the means ± SE (n = 3). (C) Cells were co-transfected with HA-tagged
c-Jun and GFP for 24 hours followed by the addition of 20 μg/ml cycloheximide for varying times. Cells were lysed, and cell lysates were
subjected to immunoblot analysis to detect HA-tagged c-Jun and GFP. The relative HA-tagged c-Jun amount was standardized by GFP.
(D) Cells were treated with vehicle (DMSO), 50 μM PYR-41, or 10 μMMG-132 for 8 hours and then lysed for immunoblot analysis to detect
c-Jun and β-actin. (E) T47D cells were treated with 10 μM MG-132 for varying times and then lysed for immunoblot analysis to detect
c-Jun and β-actin. (F) Cells were treated with 50 μM chloroquine, 10 mM NH4Cl, or 10 μMMG-132 for 8 hours and then lysed for immunoblot
analysis to detect c-Jun and β-actin.
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amount of c-Jun in less invasive cells (MCF7 and T47D), while it did
not significantly alter c-Jun abundance in invasive cells (MDA-MB-231
and MDA-MB-436; Figure 1D). MG132-induced accumulation of
c-Jun protein was very rapid; 1 hour of MG132 treatment elevated
more than eight-fold of c-Jun level in T47D cells (Figure 1E). These
results suggest that ubiquitin/proteasome system is responsible for
efficient c-Jun protein degradation in less invasive breast cancer cells.
Because lysosome system can regulate protein stability, we treated
MCF7 and T47D cells with lysosome inhibitors chloroquine and
NH4Cl for 8 hours. Immunoblot analysis showed that neither signifi-
cantly altered c-Jun level (Figure 1F), thus excluding the participation
of lysosome in c-Jun protein degradation.
Status of c-Jun Poly-ubiquitination Determines c-Jun
Abundance in Breast Cancer Cells
To determine whether the difference in c-Jun protein stability is
linked to the variation in proteasome activity between invasive and
less invasive cells, we first examined the subcellular localization of
c-Jun in MCF7 and MDA-MB-436 cells. Immunoblot analysis of
their cytoplasmic and nuclear fractions showed that c-Jun was simi-
larly present in the nucleus of both lines, and the nuclear localization
of c-Jun was not affected by MG132 treatment (Figure 2A). We
next measured the proteasome activities in the nucleus of MCF7,
MDA-MB-231, MDA-MB-436, and T47D cells. Up to 1-hour
reaction period, we did not observe significant difference in nuclear
Figure 2. The extent of poly-ubiquitination in c-Jun is different between invasive and less invasive breast cancer cells. (A) Cells were
treated with 10 μM MG132 or left untreated for 8 hours. Cells were lysed for the preparation of cytoplasmic (Cy) and nuclear (Nu) frac-
tions, and fractions were analyzed by immunoblot analysis to detect c-Jun and histone deacetylase 1 (HDAC1; indicator of nuclear fraction).
(B) Proteasome activities of breast cancer cell lines. Data are themeans ± SE (n= 3). (C) Immunofluorescence staining of c-Jun and PMSA5
in MDA-MB-231 and 10 μMMG-132–treated T47D cells. DAPI was used for nuclear staining. (D) Cells were co-transfected with HA-tagged
c-Jun and Flag-tagged ubiquitin for 1 day followed by 10 μM MG-132 treatment for 8 hours. Cells were lysed, cell lysates were immuno-
precipitated with HA mAb, and immunoprecipitates were subjected to immunoblot analysis to detect Flag-tagged ubiquitin (Ub).
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proteasome activity among these lines (Figure 2B). Immunofluores-
cence staining further showed a similar pattern of c-Jun and protea-
somal PMSA5 co-localization in MDA-MB-231 and MG132-treated
T47D cells (Figure 2C ). Identical pattern was also observed in
MDA-MB-436 and MG132-treated MCF7 cells (Figure W1). These
results indicate that the difference in c-Jun protein stability between
invasive and less invasive breast cancer cells is not caused by the
variation in nuclear proteasome activity or co-localization of c-Jun
with the proteasome.
Subsequently, we investigated the status of c-Jun poly-ubiquitination
in MG132-treated MCF7, MDA-MB-231, MDA-MB-436, and
T47D cells that had been co-transfected with HA-tagged c-Jun
and Flag-tagged ubiquitin. Immunoblot analysis of HA immuno-
precipitates with anti–Flag mAb showed that HA-tagged c-Jun was
robustly poly-ubiquitinated in MCF-7 and T47D cells, whereas the
poly-ubiquitination of HA-tagged c-Jun was very weak in MDA-
MB-231 and MDA-MB-436 cells (Figure 2D). These results suggest
that the effectiveness of c-Jun being poly-ubiquitinated determines
the abundance of c-Jun in breast cancer cells.
COP1 E3 Ligase Is Required for c-Jun Degradation in
Breast Cancer Cells
c-Jun is the substrate of CUL4, FBW7, ITCH, MEKK1, COP1,
and SAG E3 ligases. To identify the E3 ligase that regulates c-Jun
abundance in breast cancer cells, we treated MCF7 and T47D cells
with predesigned siRNA pool for each of these E3 ligases. While
Figure 3. COP1 is the E3 ligase mediating c-Jun turnover in breast cancer cells. (A) T47D and MCF7 cells were transfected with 50 nM
siRNA pool against CUL4, FBW7, ITCH, MEKK1, COP1, or SAG for 3 days. Cells were then lysed, and cell lysates were analyzed by
immunoblot analysis to detect c-Jun, COP1, and β-actin. (B) T47D and MCF7 were transfected with two sequence-distinct COP1 siRNAs
(50 nM) and then lysed for immunoblot analysis to detect c-Jun, COP1, and β-actin. (C) T47D cells were transfected with 50 nM control
or COP1 siRNA for 2 days and then co-transfected with HA-tagged c-Jun and GFP for 1 day. After adding 20 μg/ml cycloheximide for
varying times, cells were harvested and cell lysates were analyzed by immunoblot analysis to detect HA-tagged c-Jun, GFP, and COP1.
The relative HA-tagged c-Jun amount was standardized by the amount of GFP. (D) T47D cells were first treated with 50 nM control
or COP1 siRNA for 2 days and then co-transfected with HA-tagged c-Jun and Flag-tagged ubiquitin for 1 day. Cells were treated with
10 μMMG-132 treatment for 8 hours and subjected to immunoprecipitation with HA mAb. Immunoprecipitates were analyzed by immuno-
blot analysis to detect Flag-tagged ubiquitin (Ub). (E) Immunoblot analysis of c-Jun and COP1 in breast cancer cell lines.
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all of them effectively knocked down their respective targets (Fig-
ure W2), only COP1 siRNA pool markedly elevated the amount
of c-Jun in both cell lines (Figure 3A). To confirm the results gener-
ated with siRNA pool, MCF7 and T47D cells were treated with two
sequence distinct COP1 siRNAs for 3 days. Immunoblot analysis
showed that both of siRNAs increased c-Jun abundance (Figure 3B).
We next examined the effect of COP1 knockdown on c-Jun pro-
tein stability by introducing HA-tagged c-Jun into both control
and COP1-knockdown T47D cells. Cycloheximide-chasing experi-
ment showed that HA-tagged c-Jun was more stable in COP1-
knockdown T47D cells than in control T47D cells (Figure 3C ).
Immunoprecipitation experiment further revealed that the extent
of c-Jun poly-ubiquitination was significantly reduced in COP1-
knockdown cells compared with the control cells (Figure 3D).
To substantiate our findings, we investigated a potential func-
tional link between c-Jun and COP1 among breast cancer cell
lines. Immunoblot analysis revealed that lines with relatively high
c-Jun abundance (BT549, Hs578t, MDA-MB-231, and MDA-
436) displayed much less COP1 than those with relatively low
c-Jun abundance (BT474, MCF7 and T47D; Figure 3E ). This
Figure 4. Activity of GSK3β is required for efficient c-Jun protein turnover in breast cancer cells. (A) COP1 was lentivirally overexpressed
in MDA-MB-231 and MDA-MB-436 cells. Populations of cells were lysed for immunoblot analysis to detect COP1, c-Jun, and β-actin.
(B) T47D and MCF7 cells were treated with 10 μM SP600125, 10 mM LiCl, 10 μM SB216763, or 50 μM TBB for 12 hours and then lysed
for immunoblot analysis to detect c-Jun and β-actin. (C) HA-tagged c-Jun or c-Jun–T239A was co-transfected into T47D cells with GFP for
1 day followed by the addition of 20 μg/ml cycloheximide for varying times. Cells were harvested, and cell lysates were analyzed by
immunoblot analysis to detect HA-tagged c-Jun and GFP. The relative HA-tagged c-Jun amount was standardized by the amount of GFP.
(D) T47D cells were co-transfected with HA-tagged c-Jun and Flag-tagged ubiquitin for 1 day and then treated with 10 μM MG-132 for
8 hours. Cells were lysed, and cell lysates were subjected to immunoprecipitation with HA mAb. Immunoprecipitates were analyzed by
immunoblot analysis to detect Flag-tagged ubiquitin (Ub). (E) MDA-MB-231 and MDA-MB-436 cells were lentivirally transduced with
COP1 and constitutively active GSK3β either alone or together for 3 days. Cells were lysed, and cell lysates were subjected to immunoblot
analysis to detect COP1, GSK3, c-Jun, and β-actin.
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inverse correlation between c-Jun and COP1 abundance implicates
that COP1 negatively regulates the abundance of c-Jun in breast
cancer cells.
c-Jun Protein Degradation Is Sensitive to the Inhibition of
GSK3 Activity
The inverse correlation between c-Jun and COP1 abundance
prompted us to test whether enforcing COP1 expression in invasive
breast cancer cells could downregulate the amount of c-Jun. We
lentivirally introduced COP1 into MDA-MB-231 and MDA-MB-436
cells, and populations of transduced cells were analyzed for c-Jun
abundance. Immunoblot analysis showed that COP1 overexpression
was unable to decrease the level of c-Jun (Figure 4A), suggesting that
an event additional to high COP1 expression is required for rapid
c-Jun protein degradation.
The activities of CK2, JNK, and GSK3 have been shown to regu-
late c-Jun activity or stability [17,20–22]. Especially, recognition of
c-Jun by E3 ligase FBW7 necessitates GSK3-mediated phosphoryla-
tion of c-Jun [22]. To test whether phosphorylation by CK2, JNK, or
GSK3 was required for c-Jun turnover, MCF7 and T47D cells were
treated with specific inhibitors to JNK (SP600125), GSK3 (LiCl and
Figure 5. Simultaneously expressing COP1 and constitutively active GSK3β suppress breast tumorigenesis. (A) MDA-MB-231 and
MDA-MB-436 cells were lentivirally transduced with COP1 and constitutively active GSK3β either alone or together for 3 days. Popula-
tions of transduced cells were then subjected to MTT assay to measure cell proliferation. Data are the means ± SE (n = 3). #P < .01
versus empty vector (control). (B) Populations of transduced cells were subjected to transwell assay to measure cell migration. Data
are the means ± SE (n = 3). *P < .001 versus empty vector (control). (C) Control or COP1/GSK3βS9A-transduced MDA-MB-231 cells
were labeled with fluorescent dye CM-Dil and then microinjected into the perivitelline space of 48-hpf zebrafish embryos. Embryos
were imaged under a confocal microscope.
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SB216763), or CK2 (TBB). Immunoblot analysis showed that both
GSK inhibitors but neither JNK nor CK2 inhibitor led to significant
increase in the amount of c-Jun (Figure 4B), indicating the necessity of
GSK3 activity for the instability of c-Jun protein. We next generated
HA-tagged non–GSK3β-phosphorylable c-Jun (c-Jun–T239A) by
performing Thr→Ala mutagenesis at amino acid residue 239 of
c-Jun, the GSK phosphorylation site. Cycloheximide-chasing experi-
ment showed that HA-tagged c-Jun–T239A was significantly more
stable than HA-tagged c-Jun (Figure 4A), and depletion of COP1
did not affect the stability of HA-tagged c-Jun–T239A (Figure W3).
Compared to HA-tagged c-Jun, HA-tagged c-Jun–T239A was
poorly poly-ubiquitinated (Figure 4D). These results suggest that
GSK3β-mediated phosphorylation is a prerequisite for efficient poly-
ubiquitination of c-Jun and its subsequent degradation.
We next enforced the expression of COP1 or constitutive active
GSK3β (GSK3βS9A) either alone or together in MDA-MB-231 and
MDA-MB-436 cells. Although either alone did not reduce the
amount of c-Jun, their combination diminished more than 90% and
70% of c-Jun in MDA-MB-231 and MDA-MB-436 cells, respec-
tively (Figure 4E ). These results suggest that COP1 and GSK3β
work together to facilitate effective c-Jun protein degradation in breast
cancer cells.
Simultaneously Enhancing COP1 Expression and Elevating
GSK3β Activity Suppress Breast Tumorigenesis
We previously showed that the presence of c-Jun is essential for
cell migration and metastasis of invasive breast cancer cells [8]. Others
have also reported that c-Jun promotes breast cancer cell prolifera-
tion by controlling the expression of cyclins and E2F [7]. We thus
hypothesized that the reduced c-Jun abundance by combined expres-
sion of COP1 and constitutively active GSK3β would lead to the
suppression in breast tumorigenesis. To test this hypothesis, we len-
tivirally introduced COP1 and GSK3βS9A either alone or in com-
bination into MDA-MB-231 and MDA-MB-436 cells. MTT assay
showed that raising COP1 level or enforcing GSK3βS9A expression
alone moderately reduced cell proliferation, whereas their co-expression
led to much greater degree of inhibition in cell proliferation (Figure 5A).
Transwell migration assay showed that forced co-expression of COP1
and GSK3βS9A blocked about 90% of cell migration, whereas
expressing either one alone inhibited only 20% to 40% of cell migra-
tion when compared to the control (Figures 5B and W4). We further
analyzed the effect of combined COP1 and GSK3βS9A expression
in the metastasis of MDA-MB-231 and MDA-MB-436 cells using a
well-established zebrafish metastasis model [24,28,29]. Control cells
and cells with the co-expression of COP1 and GSK3βS9A were
microinjected into the perivitelline space of 48-hpf zebrafish embryos,
and embryos were imaged after 2 days. Metastasis was detected
in 44 of 48 and 46 of 56 embryos injected with control MDA-MB-
231 and MDA-MB-436 cells, respectively (Figures 5C and W5). In
contrast, metastasis was only seen in 10 of 54 and 4 of 42 embryos
injected with MDA-MB-231 and MDA-MB-436 cells co-expressing
COP1 and GSK3βS9A, respectively, while remaining embryos dis-
played cells at the site of injection (Figures 5C and W5). These
results demonstrate that simultaneously enhancing COP1 expression
and elevating GSK3β activity can effectively suppress breast cancer
cell tumorigenesis.
COP1 Expression Correlates with Recurrence-Free Survival
of Patients with Breast Cancer
As laboratory study may not always recapitulate clinical breast
malignancy, we explored the potential clinical relevance of COP1
expression in human breast cancer. To do so, we first assessed the
relationship between COP1 mRNA expression and clinical features
of breast tumors using microarray data of 126 patients with breast can-
cer obtained from the Gene Expression Omnibus. There were no
significant associations between COP1 expression (divided into low
and high expression groups by median) and pathologic parameters,
including histologic grade, tumor diameter, estrogen and proges-
terone receptor expression, and lymph node status (Table W1). How-
ever, univariate survival analysis (Kaplan-Meier method, log-rank
test) showed that higher COP1 expression was significantly associated
with high recurrence-free survival of patients (P = .006; Figure 6A).
By multivariate analysis (proportional hazard method) and encom-
passing basic prognostic factors such as tumor diameter, histologic
grade, and lymph node status in addition to COP1 expression (initial
regression model), COP1 expression status remained as an indepen-
dent positive prognostic factor in the final multivariate model (P =
.041, likelihood ratio test) along with tumor diameter and lymph
node status, with a hazard ratio of 1.69 between patients with high
and low COP1 expression (i.e., patients with low COP1 expression
have 1.69 times higher hazard for the recurrence of breast cancer
than those with high COP1 expression; Figure 6B). These results
Figure 6. COP1 expression is a positive prognostic factor for
recurrence-free survival of patients with breast cancer. (A) Univariate
survival method (Kaplan-Meier method) of patients with breast
cancer indicates a strong positive prognostic value of COP1 expres-
sion (P = .006, log-rank test). (B) Multivariate survival analysis
(proportional hazard method) shows a positive, independent prog-
nostic importance of COP1 expression (P < .05, likelihood ratio
test), in addition to the independent prognostic impact of tumor
diameter and lymph node status. HR, hazard ratio.
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also support the notion that COP1 is a negative regulator of breast
tumor progression.
Discussion
High c-Jun abundance is detected in both invasive breast cancer cell
lines and specimens of aggressive breast tumors [8,11]. However,
how c-Jun abundance is regulated in breast cancer cells is not well
understood. In this study, we showed that c-Jun protein is much more
stable in invasive breast cancer cells than less invasive ones (Figure 1),
indicating that prolonged protein stability is a major cause of high
c-Jun abundance in invasive breast cancer cells or aggressive breast
tumor specimens [8,11]. The stability of c-Jun protein in breast
cancer cells appeared to depend on whether c-Jun was efficiently
poly-ubiquitinated rather than the nuclear proteasome activity or
the ability of c-Jun to localize in the proteasomes (Figure 2). These
findings led us to hypothesize that there is lack of c-Jun–targeting E3
ubiquitin ligase in invasive breast cancer cells. With the aid of target-
specific siRNAs, we identified COP1 as an E3 ligase responsible for
c-Jun turnover in breast cancer cells as COP1 depletion enhanced
c-Jun protein stability and diminished c-Jun poly-ubiquitination in
less invasive breast cancer cells (Figure 3). In human primary T lym-
phocytes, proto-oncogene c-Abl phosphorylates c-Jun, which in turn
prevents c-Jun and ITCH interaction and thus stabilizes c-Jun [30].
Receptor for activated C-kinase 1 stabilizes c-Jun by releasing it from
FBW7 complex [31]. In this study, we showed that the levels of
c-Jun and COP1 are inversely correlated in breast cancer cells (Fig-
ure 3), implicating the low abundance of COP1 as a principal cause
of prolonged c-Jun protein stability in invasive breast cancer cells.
Phosphorylation at a specific site is the prerequisite of ubiquitina-
tion for many E3 ubiquitin ligases. For example, Skp2 ubiquitinates
and promotes the degradation of forkhead box protein O1 (FOXO1).
However, this Skp2-mediated event requires Akt-specific phosphoryla-
tion of FOXO1 at Ser-256 [32]. c-Jun is ubiquitinated by FBW7 in
various cell types, and GSK3β-mediated phosphorylation at Thr-239
is necessary for c-Jun ubiquitination to take place [22]. In this study,
we showed that blocking GSK3 activity increased c-Jun abundance
in less invasive breast cancer cells (Figure 4). Specifically, mutating
Thr-239 to Ala stabilized c-Jun protein and prevented c-Jun poly-
ubiquitination (Figure 4). Our data thus suggest that GSK3β-mediated
phosphorylation at Thr-239 is an event required for both COP1- and
FBW7-mediated c-Jun protein degradation. This possibility is further
supported by the observation that simultaneously overexpressing COP1
and elevating GSK3β activity can effectively diminish c-Jun abundance
in invasive breast cancer cells (Figure 4).
In vitro and in vivo studies have demonstrated a convincing role
of c-Jun in breast tumorigenesis. For example, enforced expression of
c-Jun confers noninvasive and hormone-dependent MCF7 cells with
an invasive and hormone-resistant phenotype [3]. In MMTV-ErbB2
transgenic breast cancer model, c-Jun deficiency led to reduced cell
migration, invasion, and mammosphere formation of erbB2-induced
mammary tumors [5]. In this study, we showed that simultaneously
raising COP1 level and elevating GSK3β activity suppressed in vitro
cell growth/migration and in vivo metastasis of invasive breast cancer
cells (Figure 5). Taken together, our study presents strong evidence
that both high COP1 expression and GSK3β activity negatively impact
breast tumor progression and metastasis.
There are evidences for both up-regulation and loss of COP1 in
cancers [14,33,34]. It remains to be determined if overexpression of
COP1 promotes tumorigenesis or is the consequence of tumor for-
mation; however, mice with partial loss of COP1 function or tissue-
specific COP1 ablation strongly suggest that COP1 is a tumor
suppressor [14,35]. Using publicly available breast tumor gene expres-
sion microarray database, we found that reduced COP1 expression
correlated with poorer disease-free survival and COP1 expression is
an independent positive prognostic factor for recurrence-free survival
(Figure 6). Our study adds strong evidences that COP1 is a suppressor
of breast tumor progression.
Although our mechanistic study was performed with the established
breast cancer cell lines, our observation that high COP1 expression
correlated with better disease-free survival of patients with breast
cancer supports the results generated from our experimental studies.
To conclude, our study suggests that COP1 and GSK3β cooperate
to promote c-Jun degradation and, hence, subsequent inhibition of
breast tumor progression and metastasis.
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Supplemental Information
Antibody Information
c-Jun rabbit mAb: CS-9165, Cell Signaling Technology (Danvers,
MA); titer 1:1000 (immunoblot analysis)
COP1 rabbit polyclonal antibody: A300-894A, Bethyl Laboratories
(Montgomery, TX); titer 1:1000 (immunoblot analysis)
GSK3 rabbit mAb: SC-5676, Cell Signaling Technology;
titer 1:1000 (immunoblot analysis)
HA rabbit mAb: CS-5017, Cell Signaling Technology;
titer 1:1000 (immunoblot analysis)
β-Actin mouse mAb: SC-47778, Santa Cruz Biotechnology (Santa
Cruz, CA); titer 1:500 (immunoblot analysis)
Flag mouse mAb: F 3165, Sigma; titer 1:1000 (immuno-
blot analysis)
c-Jun mouse mAb: BD-610327, BD Biosciences (San Jose, CA);
titer 1:100 (immunofluorescence staining)
PSMA5 (proteasome S5A subunit) rabbit polyclonal antibody:
CS-2457, Cell Signaling Technology; titer 1:50 (immuno-
fluorescence staining)
Information for Primers Used in Quantitative Reverse
Transcription–Polymerase Chain Reaction
COP1 F CCACAGGTGGCAGATATTTCAA
COP1 R CATTGGCCAAATCAAGGTTATCTT
FBW7 F AATGGCCAAGGGCAACAA
FBW7 R CATTCCTGGAGGCCTGTAGGT
ITCH F GATGGCTCCAGATCCAAGGA
ITCH R TGCATCTTCAGGGTCATCTGAT
CUL4A F GAATCAGAGTGACTCAGGCCCTATA
CUL4A R GGCCAGTAGCCCATTGTGA
SAG F AACAATCGCTGCCCTCTCT
SAG R CTCATTTGCCGATTCTTTGGA
MEKK1 F CAAACCGCCGTGTTAACAAA
MEKK1 R GGCCCTATCTGCTGCAGTAAGT
β-Actin F CCAGCTCACCATGGATGATG
β-Actin R ATGCCGGAGCCGTTGTC
Sequences of COP1 siRNAs
siCOP1 #1, AAAAGAAAUGACCUGCAAUUCGATTGGA-
TCCAATCGAATTGCAGGTCATTTC
siCOP1 #2, AAAAAAACAGCCUUGGUAUAAUATTGGA-
TCCAATATTATACCAAGGCTGTTT
Figure W3. Depletion of COP1 does not alter protein stability of c-Jun–T239A. T47D cells were treated with control or COP1 siRNA for
2 days. HA-tagged c-Jun–T239A was then co-transfected into these cells with GFP for 1 day followed by the addition of 20 μg/ml cyclo-
heximide for varying times. Cells were harvested, and cell lysates were analyzed by immunoblot analysis to detect HA-tagged c-Jun
and GFP. The relative HA-tagged c-Jun amount was standardized by the amount of GFP.
Figure W1. Colocalization of c-Jun and PMSA5. Immunofluorescence staining of c-Jun and PMSA5 in MDA-MB-436 and 10 μMMG132-
treated MCF7 cells. DAPI was used to stain nucleus.
Figure W2. siRNA-mediated knockdown effect of c-Jun–targeting
E3 ligases. MCF7 and T47D cells were transfected with 50 nM con-
trol or siRNA pool against CUL4, FBW7, ITCH, MEKK1, COP1, or
SAG for 3 days. Total RNA was extracted from these cells and
subjected to quantitative reverse transcription–polymerase chain
reaction with the respective primers. β-Actin mRNA was used as
the internal control for standardization.
Figure W4. Simultaneously expressing COP1 and constitutively
active GSK3β block cell migration of invasive breast cancer cells.
COP1 and GSK3β(CA) were lentivirally transduced into MDA-MB-231
and MDA-MB-436 cells either alone or together. Populations of trans-
duced cells were added into transwells and allowed to migrate for
4 hours. Images are crystal violet–stained migratory cells on the
undersurface of transwells.
Figure W5. Simultaneously expressing COP1 and constitutively
active GSK3β suppress breast cancer cell metastasis. MDA-MB-436
cells were lentivirally transduced with COP1 and constitutively active
GSK3β together for 3 days. Control and COP1/GSK3βS9A-transduced
MDA-MB-436 cells were then labeled with fluorescent dye CM-Dil
and microinjected into the perivitelline space of 48-hpf zebrafish
embryos. Embryos were imaged under a confocal microscope.
Table W1. Clinicopathologic Correlates of COP1 Expression in Human Breast Cancer.
Clinical Features COP1 Expression* P Value†
Low (%) High (%)
Histologic grade .28
1 5 6
2-3 26 77
Tumor diameter .72
<2 cm 6 22
≥2 cm 26 70
Lymph node status .71
Negative 14 48
Positive 15 40
ER receptor .46
Negative 13 44
Positive 20 46
PR receptor .89
Negative 15 42
Positive 12 35
PR indicates progesterone receptor.
*Low/high by median (low, COP1 < 0; high, COP1 ≥ 0 expression value).
†Pearson χ2 test.
